Shots:Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platformFurthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disordersUpon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and…
